Compare HWM & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWM | REGN |
|---|---|---|
| Founded | 1888 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.6B | 84.3B |
| IPO Year | 2005 | 1995 |
| Metric | HWM | REGN |
|---|---|---|
| Price | $220.17 | $959.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 28 |
| Target Price | $296.29 | ★ $977.93 |
| AVG Volume (30 Days) | ★ 3.7M | 900.8K |
| Earning Date | 10-29-2026 | 10-30-2026 |
| Dividend Yield | 0.25% | ★ 0.40% |
| EPS Growth | ★ 32.03 | 8.19 |
| EPS | 4.18 | ★ 37.37 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $24.86 | $30.96 |
| Revenue Next Year | $13.49 | $7.28 |
| P/E Ratio | $53.25 | ★ $25.47 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $183.52 | $591.52 |
| 52 Week High | $310.00 | $991.73 |
| Indicator | HWM | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.38 | 68.51 |
| Support Level | $183.52 | $747.82 |
| Resistance Level | $229.57 | $991.73 |
| Average True Range (ATR) | 8.74 | 36.53 |
| MACD | 3.20 | 5.40 |
| Stochastic Oscillator | 84.84 | 81.08 |
Howmet Aerospace Inc offers engineered solutions for the aerospace and transportation industries. The company's products and solutions include investment castings for jet engines and industrial gas turbines; seamless rolled rings for jet engines; fastening systems for aerospace, industrial and commercial transportation applications; forged jet engine components (e.g., jet engine disks); machined and forged aircraft parts; and forged aluminum commercial vehicle wheels, all of which are sold directly to customers or through distributors. It has four reportable segments: Engine Products, which derives key revenue, Fastening Systems, Engineered Structures, and Forged Wheels. Geographically, the company derives maximum revenue from the USA, followed by France, Japan, Germany, and other markets.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.